Fair Value Measurements and Marketable Equity Securities - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 11, 2025	Aug. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure			$ 1,104,000		$ 1,104,000
Aggregate proceeds from sale of marketable equity securities					8,316,000	$ 23,098,000
Marketable equity securities outstanding			$ 104,996,000		$ 104,996,000		$ 107,309,000
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in equity securities at fair value sold number of shares			0	0	737,466	1,725,902
Weighted average price per share of investment sold					$ 11.28	$ 13.38
Aggregate proceeds from sale of marketable equity securities					$ 8,300,000	$ 23,100,000
Deep 6 Acquisition [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of held back shares in connection with business acquisition	17,372
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure			$ 1,104,000		1,104,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure			0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure			0		0
Gain or loss due to change in fair value for assets and liabilities measured at fair value using significant unobservable inputs (Level 3)			$ 0		0
Company recognized gain (loss) due change fair value of warrant liability				$ 1,700,000		$ 900,000
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant issued					$ 100,000,000
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Class Of Warrant Share Issued			9,218,800		9,218,800
Common stock purchase price		$ 18,400,000
Purchase of additional shares of common stock		3,500,000
Purchase of additional shares of common stock value		$ 17,700,000
Outstanding common stock percentage		20.00%
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.5		$ 1.5
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.5		$ 2.5
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Class Of Warrant Excisable At Cash			4,609,400		4,609,400
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Class Of Warrant Excisable At Cash			4,609,400		4,609,400
Contingent Consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure			$ 800,000		$ 800,000
Contingent Consideration [Member] | Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock					35,000
Contingent Consideration [Member] | Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock					35,000